vs

Side-by-side financial comparison of RB GLOBAL INC. (RBA) and DENTSPLY SIRONA Inc. (XRAY). Click either name above to swap in a different company.

RB GLOBAL INC. is the larger business by last-quarter revenue ($1.2B vs $961.0M, roughly 1.3× DENTSPLY SIRONA Inc.). RB GLOBAL INC. runs the higher net margin — 9.1% vs -15.2%, a 24.3% gap on every dollar of revenue. On growth, DENTSPLY SIRONA Inc. posted the faster year-over-year revenue change (6.2% vs 5.4%). RB GLOBAL INC. produced more free cash flow last quarter ($186.5M vs $60.0M). Over the past eight quarters, RB GLOBAL INC.'s revenue compounded faster (6.3% CAGR vs 0.4%).

Ritchie Bros. Auctioneers (RBA), or simply Ritchie Bros., is a publicly traded company legally domiciled in Canada with headquarters in Westchester, Illinois. Its common shares are traded on the Toronto Stock Exchange and the New York Stock Exchange.

Dentsply Sirona Inc. is an American dental equipment manufacturer and dental consumables producer that markets its products in over 120 countries. It has factories in 21 countries. The present company is largely the result of a merger in 1993 in which Gendex Corporation acquired Dentsply International Inc. for $590 million.

RBA vs XRAY — Head-to-Head

Bigger by revenue
RBA
RBA
1.3× larger
RBA
$1.2B
$961.0M
XRAY
Growing faster (revenue YoY)
XRAY
XRAY
+0.8% gap
XRAY
6.2%
5.4%
RBA
Higher net margin
RBA
RBA
24.3% more per $
RBA
9.1%
-15.2%
XRAY
More free cash flow
RBA
RBA
$126.5M more FCF
RBA
$186.5M
$60.0M
XRAY
Faster 2-yr revenue CAGR
RBA
RBA
Annualised
RBA
6.3%
0.4%
XRAY

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
RBA
RBA
XRAY
XRAY
Revenue
$1.2B
$961.0M
Net Profit
$109.7M
$-146.0M
Gross Margin
46.1%
Operating Margin
14.7%
-14.5%
Net Margin
9.1%
-15.2%
Revenue YoY
5.4%
6.2%
Net Profit YoY
-7.4%
66.0%
EPS (diluted)
$0.53
$-0.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RBA
RBA
XRAY
XRAY
Q4 25
$1.2B
$961.0M
Q3 25
$1.1B
$904.0M
Q2 25
$1.2B
$936.0M
Q1 25
$1.1B
$879.0M
Q4 24
$1.1B
$905.0M
Q3 24
$981.8M
$951.0M
Q2 24
$1.1B
$984.0M
Q1 24
$1.1B
$953.0M
Net Profit
RBA
RBA
XRAY
XRAY
Q4 25
$109.7M
$-146.0M
Q3 25
$95.5M
$-427.0M
Q2 25
$109.8M
$-45.0M
Q1 25
$113.4M
$20.0M
Q4 24
$118.5M
$-430.0M
Q3 24
$76.1M
$-494.0M
Q2 24
$111.1M
$-4.0M
Q1 24
$107.4M
$18.0M
Gross Margin
RBA
RBA
XRAY
XRAY
Q4 25
46.1%
Q3 25
48.8%
Q2 25
52.4%
Q1 25
53.0%
Q4 24
49.3%
Q3 24
52.1%
Q2 24
51.9%
Q1 24
53.1%
Operating Margin
RBA
RBA
XRAY
XRAY
Q4 25
14.7%
-14.5%
Q3 25
14.5%
-24.1%
Q2 25
15.9%
-13.7%
Q1 25
17.1%
7.2%
Q4 24
18.1%
-56.2%
Q3 24
15.6%
-48.6%
Q2 24
18.4%
5.1%
Q1 24
18.7%
4.4%
Net Margin
RBA
RBA
XRAY
XRAY
Q4 25
9.1%
-15.2%
Q3 25
8.7%
-47.2%
Q2 25
9.3%
-4.8%
Q1 25
10.2%
2.3%
Q4 24
10.4%
-47.5%
Q3 24
7.8%
-51.9%
Q2 24
10.1%
-0.4%
Q1 24
10.1%
1.9%
EPS (diluted)
RBA
RBA
XRAY
XRAY
Q4 25
$0.53
$-0.74
Q3 25
$0.43
$-2.14
Q2 25
$0.53
$-0.22
Q1 25
$0.55
$0.10
Q4 24
$0.58
$-2.09
Q3 24
$0.36
$-2.46
Q2 24
$0.54
$-0.02
Q1 24
$0.53
$0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RBA
RBA
XRAY
XRAY
Cash + ST InvestmentsLiquidity on hand
$531.5M
$326.0M
Total DebtLower is stronger
$2.3B
$2.3B
Stockholders' EquityBook value
$5.6B
$1.3B
Total Assets
$12.1B
$5.4B
Debt / EquityLower = less leverage
0.42×
1.70×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RBA
RBA
XRAY
XRAY
Q4 25
$531.5M
$326.0M
Q3 25
$674.7M
$363.0M
Q2 25
$710.2M
$359.0M
Q1 25
$578.1M
$398.0M
Q4 24
$533.9M
$272.0M
Q3 24
$650.7M
$296.0M
Q2 24
$599.5M
$279.0M
Q1 24
$462.8M
$291.0M
Total Debt
RBA
RBA
XRAY
XRAY
Q4 25
$2.3B
$2.3B
Q3 25
$2.6B
Q2 25
$2.6B
Q1 25
$2.6B
Q4 24
$2.6B
$1.7B
Q3 24
$2.7B
Q2 24
$2.8B
Q1 24
$2.9B
Stockholders' Equity
RBA
RBA
XRAY
XRAY
Q4 25
$5.6B
$1.3B
Q3 25
$5.5B
$1.5B
Q2 25
$5.5B
$2.0B
Q1 25
$5.3B
$2.0B
Q4 24
$5.2B
$1.9B
Q3 24
$5.2B
$2.5B
Q2 24
$5.2B
$3.1B
Q1 24
$5.1B
$3.3B
Total Assets
RBA
RBA
XRAY
XRAY
Q4 25
$12.1B
$5.4B
Q3 25
$12.2B
$5.7B
Q2 25
$12.2B
$6.1B
Q1 25
$11.9B
$6.0B
Q4 24
$11.8B
$5.8B
Q3 24
$11.9B
$6.6B
Q2 24
$12.1B
$6.9B
Q1 24
$12.0B
$7.1B
Debt / Equity
RBA
RBA
XRAY
XRAY
Q4 25
0.42×
1.70×
Q3 25
0.47×
Q2 25
0.47×
Q1 25
0.50×
Q4 24
0.50×
0.90×
Q3 24
0.52×
Q2 24
0.55×
Q1 24
0.58×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RBA
RBA
XRAY
XRAY
Operating Cash FlowLast quarter
$255.2M
$101.0M
Free Cash FlowOCF − Capex
$186.5M
$60.0M
FCF MarginFCF / Revenue
15.5%
6.2%
Capex IntensityCapex / Revenue
5.7%
4.3%
Cash ConversionOCF / Net Profit
2.33×
TTM Free Cash FlowTrailing 4 quarters
$719.2M
$104.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RBA
RBA
XRAY
XRAY
Q4 25
$255.2M
$101.0M
Q3 25
$239.7M
$79.0M
Q2 25
$326.5M
$48.0M
Q1 25
$156.8M
$7.0M
Q4 24
$184.5M
$87.0M
Q3 24
$285.4M
$141.0M
Q2 24
$337.3M
$208.0M
Q1 24
$124.8M
$25.0M
Free Cash Flow
RBA
RBA
XRAY
XRAY
Q4 25
$186.5M
$60.0M
Q3 25
$188.5M
$40.0M
Q2 25
$241.7M
$16.0M
Q1 25
$102.5M
$-12.0M
Q4 24
$127.9M
$36.0M
Q3 24
$248.5M
$98.0M
Q2 24
$308.6M
$156.0M
Q1 24
$79.6M
$-9.0M
FCF Margin
RBA
RBA
XRAY
XRAY
Q4 25
15.5%
6.2%
Q3 25
17.3%
4.4%
Q2 25
20.4%
1.7%
Q1 25
9.2%
-1.4%
Q4 24
11.2%
4.0%
Q3 24
25.3%
10.3%
Q2 24
28.2%
15.9%
Q1 24
7.5%
-0.9%
Capex Intensity
RBA
RBA
XRAY
XRAY
Q4 25
5.7%
4.3%
Q3 25
4.7%
4.3%
Q2 25
7.2%
3.4%
Q1 25
4.9%
2.2%
Q4 24
5.0%
5.6%
Q3 24
3.8%
4.5%
Q2 24
2.6%
5.3%
Q1 24
4.2%
3.6%
Cash Conversion
RBA
RBA
XRAY
XRAY
Q4 25
2.33×
Q3 25
2.51×
Q2 25
2.97×
Q1 25
1.38×
0.35×
Q4 24
1.56×
Q3 24
3.75×
Q2 24
3.04×
Q1 24
1.16×
1.39×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

RBA
RBA

Buyer Revenue$577.2M48%
Seller Revenue$255.2M21%
CA$199.0M17%
Other$124.7M10%
AU$47.3M4%

XRAY
XRAY

Essential Dental Solutions$372.0M39%
Equipment And Instruments$160.0M17%
Implants And Prosthetics$150.0M16%
CADCAM$139.0M14%
Wellspect Healthcare$88.0M9%
Orthodontics$52.0M5%

Related Comparisons